At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
ACZ885 +1 moredrug
Likely dose
ACZ885 4 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multiple-dose, Subject- and Investigator-blinded, Placebo-controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia
In Brief
A Phase 2 clinical trial evaluating ACZ885 and Placebo for Sickle Cell Anemia. Completed, enrolled 49 participants across 15 sites in 7 countries.
Detailed Summary
The study assesses the efficacy, safety and tolerability of ACZ885 (canakinumab) in pediatric and young adult patients with sickle cell anemia (SCA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Anemia
CountriesCanada, Germany, Israel, South Africa, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartApr 2017
Primary CompletionJun 2019
Study CompletionApr 2020
TodayJul 2026
First PostedNov 10, 2016
Enrollment StartApr 5, 2017
Primary CompletionJun 27, 2019
Study CompletionApr 27, 2020
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 9.6 years ago
Interventions
ACZ885drug
Monthly doses of 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects
Placebodrug
Monthly doses of placebo to match the administered dose of canakinumab s.c.